Abstract: An electronic device includes a substrate and a circuit having a plurality of electrically-conductive components disposed on the substrate. The plurality of electrically-conductive components includes first, second and third electrically-conductive components. The third electrically-conductive component has a first end portion forming a first interface with the first electrically-conductive component and a second end portion forming a second interface with the second electrically conductive component. The first electrically-conductive component is made of a first material including a first metal. The second electrically-conductive component is made of a second material including the first metal. The third electrically-conductive component is made of a third material including a gallium-based alloy and a metallic filler.

Abstract: Disclosed herein are embodiments of a compound that inhibits c-Abl tyrosine kinase (also referred to herein as “c-Abl”). The compound embodiments described herein are novel c-Abl inhibitors that can bind to c-Abl at an allosteric site and inhibit its activity in various pathways. The compound embodiments also are capable of crossing the blood brain barrier and therefore are useful in inhibiting c-Abl activity as it affects pathways and/or proteins in the brain. The compound embodiments described herein are effective therapeutic agents for treating diseases involving c-Abl, such as cancers, motor neuron diseases, and neurodegenerative diseases. Also disclosed herein are embodiments of methods for making and using the c-Abl inhibitory compound embodiments.

Abstract: Disclosed herein are embodiments of a compound that inhibits c-Abl tyrosine kinase (also referred to herein as “c-Abl”). The compound embodiments described herein are novel c-Abl inhibitors that can bind to c-Abl at an allosteric site and inhibit its activity in various pathways. The compound embodiments also are capable of crossing the blood brain barrier and therefore are useful in inhibiting c-Abl activity as it affects pathways and/or proteins in the brain. The compound embodiments described herein are effective therapeutic agents for treating diseases involving c-Abl, such as cancers, motor neuron diseases, and neurodegenerative diseases. Also disclosed herein are embodiments of methods for making and using the c-Abl inhibitory compound embodiments.

Abstract: A camera device for integration into a wearable device is presented. The camera device includes an image sensor, a lens assembly, a first high density interconnect (HDI) tape substrate, a second HDI tape substrate, and a molded plastic layer. The molded plastic layer is sandwiched between the first and second HDI tape substrates. A wearable device with at least one soft electrode is further presented. The at least one soft electrode includes a conductive coating applied to an elastomer substrate and monitors electrical signals generated by a wearer of the wearable device to initiate an appropriate action. A method of forming an aggregate coating for a wearable device is further presented. One or more thin films are applied to a surface of the wearable device, and a paint coating is applied to a surface of the one or more thin films to form the aggregate coating.

Abstract: A polymer film comprising at least two properties selected from (i) a thickness of not greater than 100 ?m; (ii) a tensile modulus according to ASTM D882 of at least 5 GPa; (iii) a first optical transparency according to ASTM D1746-15 at 380 nm of less than 50%; (iii) a Yellowing Index according to ASTM E313-15e1 of not greater than 2.5; (iv) a haze as determined according to ASTM D1003-13 of not greater than 1.5%; (v) a pencil hardness of greater than 1H; (vi) a coefficient of moisture expansion (‘CME’) as determined according to ASTM D5229/D5229M-14 of not greater than 50 ppm; (vii) an elongation at break as determined according to ASTM D5034-09 (2017) of at least 10%; or (viii) a folding endurance as determined according to ASTM D2176-16 at a radius of 1 mm of at least 10,000 folds.

Abstract: Disclosed herein are embodiments of a compound that inhibits c-Abl tyrosine kinase (also referred to herein as “c-Abl”). The compound embodiments described herein are novel c-Abl inhibitors that can bind to c-Abl at an allosteric site and inhibit its activity in various pathways. The compound embodiments also are capable of crossing the blood brain barrier and therefore are useful in inhibiting c-Abl activity as it affects pathways and/or proteins in the brain. The compound embodiments described herein are effective therapeutic agents for treating diseases involving c-Abl, such as cancers, motor neuron diseases, and neurodegenerative diseases. Also disclosed herein are embodiments of methods for making and using the c-Abl inhibitory compound embodiments.

Abstract: The present disclosure describes surface formulations that form a layer on surfaces and comprise a phenol selected from: (I), (II), (III), (IV) or (V), with detailed descriptions of variables herein.

Abstract: Methods and systems are described for applying a configuration to networking devices. A configuration and networking device filter may be received. The networking device filter may be used to search for target networking devices. A common schema may be generated for the target networking devices. The configuration may be compared to the common schema to determine whether the configuration is valid for the target networking devices. A plurality of commands may be generated to apply the configuration to the target networking devices. The commands may be executed, thereby applying the configuration to the target networking devices.

Abstract: Methods and systems are described for applying a configuration to networking devices. A configuration and networking device filter may be received. The networking device filter may be used to search for target networking devices. A common schema may be generated for the target networking devices. The configuration may be compared to the common schema to determine whether the configuration is valid for the target networking devices. A plurality of commands may be generated to apply the configuration to the target networking devices. The commands may be executed, thereby applying the configuration to the target networking devices.

Abstract: A polymer composite includes a functionalized polyisobutylene and an additional polyisobutylene-containing material. The functionalized polyisobutylene includes an ?-lipoic acid functional group. A method for producing the polymer composite includes providing the additional polyisobutylene-containing material as a substrate having a surface, and coating the surface of the substrate with the functionalized polyisobutylene. A method for producing a coated substrate including the polymer composite includes providing a polymer combination including the functionalized polyisobutylene and the additional polyisobutylene-containing material, and depositing the polymer combination on to a substrate to thereby form the coated substrate.

Abstract: A polymer composite includes a functionalized polyisobutylene and an additional polyisobutylene-containing material. One or more methods of making the polymer composite are also provided. Where the functionalized polyisobutylene is applied to a polyisobutylene-containing material, the method of applying the functionalized polyisobutylene compound can be described as a modular method.

Abstract: A polymer composite includes a functionalized polyisobutylene and an additional polyisobutylene-containing material. One or more methods of making the polymer composite are also provided. Where the functionalized polyisobutylene is applied to a polyisobutylene-containing material, the method of applying the functionalized polyisobutylene compound can be described as a modular method.

Abstract: A rheometer for measuring non-Newtonian fluids is disclosed. The rheometer includes capillaries with piezometers therein, a pump, flow control valves, flow, density, and speed meters, and a controller. The rheometer has application in providing for online measurements of parameters including viscosity and yield stress in mining suspensions based upon laminar transportation of the suspensions by the capillaries.

Abstract: This invention relates to the use of imatinib mesylate for the treatment of metabolism disorders characterized by neurodegeneration, in particular a metabolism disorder characterized by an inability to metabolize lipids such as in persons with Niemann-Pick Type C disease. More specifically, this invention relates to a method of treating neurodegenerative disease, comprising administering a therapeutically effective amount of a compound derived from imatinib mesylate or a pharmaceutically acceptable salt thereof.